CA2187932A1 - Sulfamides substitues utilises comme agonistes selectifs vis-a-vis des recepteurs .beta.3-adrenergiques, pour le traitement du diabete et de l'obesite - Google Patents
Sulfamides substitues utilises comme agonistes selectifs vis-a-vis des recepteurs .beta.3-adrenergiques, pour le traitement du diabete et de l'obesiteInfo
- Publication number
- CA2187932A1 CA2187932A1 CA002187932A CA2187932A CA2187932A1 CA 2187932 A1 CA2187932 A1 CA 2187932A1 CA 002187932 A CA002187932 A CA 002187932A CA 2187932 A CA2187932 A CA 2187932A CA 2187932 A1 CA2187932 A1 CA 2187932A1
- Authority
- CA
- Canada
- Prior art keywords
- ethyl
- phenyl
- amino
- hydroxy
- pyridinyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/47—Y being a hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne des sulfamides substitués ayant la formule I. Ce sont des agonistes sélectifs vis-à-vis des récepteurs .beta.¿3?-adrénergiques avec très peu d'activité vis-à-vis des récepteurs .beta.¿1? et .beta.¿2?-adrénergiques. Par conséquent, ces composés sont capables d'augmenter la lipolyse et la consommation énergétique des cellules. Ces composés sont très efficaces pour le traitement du diabète juvénile et de l'obésité. Ces composés peuvent également être utilisés pour diminuer les niveaux des triglycérides et du cholestérol, pour augmenter la concentration des lipoprotéines de haute densité ou encore pour accélérer le transit intestinal. En plus ces composés peuvent être utilisés pour combattre les inflammations d'origine nerveuse ou comme antidépresseurs. On prépare ces composés en couplant un aminoalkylphényl sulfamide avec un époxyde portant un substituant approprié. On décrit également des compositions et les méthodes d'utilisation des composés dans le traitement du diabète et de l'obésité, pour diminuer les niveaux des triglycérides et du cholestérol, pour augmenter le niveau des lipoprotéines de haute densité ou encore pour accélérer le transit intestinal.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23316694A | 1994-04-26 | 1994-04-26 | |
US40456595A | 1995-03-21 | 1995-03-21 | |
US08/404,566 US5541197A (en) | 1994-04-26 | 1995-03-21 | Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity |
US404,566 | 1995-03-21 | ||
US404,565 | 1995-03-21 | ||
US233,166 | 1995-03-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2187932A1 true CA2187932A1 (fr) | 1995-11-02 |
Family
ID=27398391
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002187932A Abandoned CA2187932A1 (fr) | 1994-04-26 | 1995-04-21 | Sulfamides substitues utilises comme agonistes selectifs vis-a-vis des recepteurs .beta.3-adrenergiques, pour le traitement du diabete et de l'obesite |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP0757674A1 (fr) |
JP (1) | JP3149186B2 (fr) |
CN (1) | CN1149869A (fr) |
AU (1) | AU687558B2 (fr) |
CA (1) | CA2187932A1 (fr) |
CZ (1) | CZ315196A3 (fr) |
FI (1) | FI964314A (fr) |
HU (1) | HUT76442A (fr) |
IL (1) | IL113410A (fr) |
NO (1) | NO964548L (fr) |
NZ (1) | NZ284718A (fr) |
PL (1) | PL316969A1 (fr) |
SK (1) | SK136196A3 (fr) |
WO (1) | WO1995029159A1 (fr) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5705515A (en) * | 1994-04-26 | 1998-01-06 | Merck & Co., Inc. | Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity |
GB2305665A (en) * | 1995-09-26 | 1997-04-16 | Merck & Co Inc | Selective ß3 agonists for the treatment of diabetes aand obesity |
EP0858340A4 (fr) * | 1995-11-01 | 1999-12-29 | Merck & Co Inc | Traitement combine du diabete et de l'obesite |
AU715233B2 (en) | 1996-01-10 | 2000-01-20 | Asahi Kasei Kogyo Kabushiki Kaisha | Novel tricyclic compounds and drug compositions containing the same |
AU712057B2 (en) * | 1996-06-07 | 1999-10-28 | Merck & Co., Inc. | Oxadiazole benzenesulfonamides as selective beta3 agonists for the treatment of diabetes and obesity |
AR007739A1 (es) * | 1996-07-22 | 1999-11-10 | Merck & Co Inc | Un proceso para la preparacion de n-(r)-(2-hidroxi-2-piridina-3-il-etil) -2-(4-nitro-fenil)-acetamida |
US5908830A (en) * | 1996-10-31 | 1999-06-01 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes and obesity |
ATE247641T1 (de) * | 1996-11-14 | 2003-09-15 | Pfizer | Pyridin-zwischenprodukte, verwendbar zur herstellung von beta-adrenergischen rezeptor- agonisten |
TR199901063T2 (xx) | 1996-11-14 | 1999-08-23 | Pfizer Inc. | �kame edilmi� piridinler i�in i�lem. |
EA199900692A1 (ru) * | 1997-01-28 | 2000-02-28 | Мерк Энд Ко., Инк. | БЕНЗОЛСУЛЬФАМИДЫ ТИАЗОЛА КАК βАГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ ДИАБЕТА И ОЖИРЕНИЯ |
US6011048A (en) * | 1997-01-28 | 2000-01-04 | Merck & Co., Inc. | Thiazole benzenesulfonamides as β3 agonists for treatment of diabetes and obesity |
ID23989A (id) * | 1997-10-17 | 2000-06-14 | Yamanouchi Pharma Co Ltd | Turunan-turunan amida atau garam-garamnya |
JP2001526281A (ja) * | 1997-12-19 | 2001-12-18 | バイエル・コーポレーシヨン | ベータ−3アドレナリンレセプターアゴニストとして有用な新規なスルホンアミド置換クロマン誘導体 |
US6469031B1 (en) | 1998-12-18 | 2002-10-22 | Bayer Corporation | Carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists |
US6051586A (en) * | 1997-12-19 | 2000-04-18 | Bayer Corporation | Sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists |
US6043253A (en) * | 1998-03-03 | 2000-03-28 | Merck & Co., Inc. | Fused piperidine substituted arylsulfonamides as β3-agonists |
US6730792B2 (en) * | 2000-07-13 | 2004-05-04 | Eli Lilly And Company | β3 adrenergic agonists |
US6410734B1 (en) | 2000-07-17 | 2002-06-25 | Wyeth | 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists |
US6525202B2 (en) | 2000-07-17 | 2003-02-25 | Wyeth | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
US6537994B2 (en) | 2000-07-17 | 2003-03-25 | Wyeth | Heterocyclic β3 adrenergic receptor agonists |
US6451814B1 (en) * | 2000-07-17 | 2002-09-17 | Wyeth | Heterocyclic β-3 adrenergic receptor agonists |
US6465501B2 (en) | 2000-07-17 | 2002-10-15 | Wyeth | Azolidines as β3 adrenergic receptor agonists |
US6498170B2 (en) | 2000-07-17 | 2002-12-24 | Wyeth | Cyclamine sulfonamides as β-3 adrenergic receptor agonists |
DE60120748T2 (de) | 2000-11-10 | 2007-05-16 | Eli Lilly And Co., Indianapolis | 3-substituierte oxindolderivate als beta-3-agonisten |
AR035605A1 (es) | 2000-12-11 | 2004-06-16 | Bayer Corp | Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores |
EP1236723A1 (fr) * | 2001-03-01 | 2002-09-04 | Pfizer Products Inc. | Dérivés de sulfamide utiles comme agonistes de beta3 et leurs applications pharmaceutiques |
AR035858A1 (es) | 2001-04-23 | 2004-07-21 | Bayer Corp | Derivados de cromano 2,6-sustituidos,composiciones farmaceuticas,uso de dichos derivados para la manufactura de medicamentos utiles como agonistas adrenorreceptores beta-3 |
ATE325119T1 (de) | 2001-08-14 | 2006-06-15 | Lilly Co Eli | 3-substituierte oxindol-beta-3-agonisten |
DE60215028T2 (de) | 2001-08-14 | 2007-03-15 | Eli Lilly And Co., Indianapolis | Indol derivate als beta-3-adrenerge agonisten zur behandlung von typ 2 diabetes |
DE60228990D1 (de) | 2001-10-25 | 2008-10-30 | Asahi Kasei Pharma Corp | Bicyclische verbindung |
DE60225174T2 (de) | 2001-11-20 | 2009-02-12 | Eli Lilly And Co., Indianapolis | Beta-3 adrenergische agonisten |
WO2003044016A1 (fr) | 2001-11-20 | 2003-05-30 | Eli Lilly And Company | Agonistes $g(b)3 a base d'oxindole 3-substitue |
AU2002357084A1 (en) | 2002-01-11 | 2003-07-30 | Eli Lilly And Company | 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as beta3 agonists |
US20040127733A1 (en) | 2002-10-31 | 2004-07-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New beta-agonists, processes for preparing them and their use as pharmaceutical compositions |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
JPWO2004106290A1 (ja) * | 2003-05-14 | 2006-07-20 | キッセイ薬品工業株式会社 | アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途 |
US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
DE102004021779A1 (de) | 2004-04-30 | 2005-11-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
JP4879988B2 (ja) | 2005-09-29 | 2012-02-22 | メルク・シャープ・エンド・ドーム・コーポレイション | メラノコルチン−4受容体モジュレーターとしてのアシル化スピロピペリジン誘導体 |
DE102005052127A1 (de) | 2005-10-28 | 2007-05-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue indol-haltige Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
JP2007145819A (ja) * | 2005-10-28 | 2007-06-14 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
EP2083831B1 (fr) | 2006-09-22 | 2013-12-25 | Merck Sharp & Dohme Corp. | Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras |
EP2145884B1 (fr) | 2007-04-02 | 2014-08-06 | Msd K.K. | Dérivé d'indoledione |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
US7879802B2 (en) | 2007-06-04 | 2011-02-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US20100120694A1 (en) | 2008-06-04 | 2010-05-13 | Synergy Pharmaceuticals, Inc. | Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders |
EP2321341B1 (fr) | 2008-07-16 | 2017-02-22 | Synergy Pharmaceuticals Inc. | Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres |
AU2009301797B2 (en) | 2008-10-09 | 2012-03-01 | Asahi Kasei Pharma Corporation | Indazole derivative |
CA2740772A1 (fr) | 2008-10-09 | 2010-04-15 | Asahi Kasei Pharma Corporation | Compose d'indazole |
EP2348857B1 (fr) | 2008-10-22 | 2016-02-24 | Merck Sharp & Dohme Corp. | Nouveaux dérivés de benzimidazole cycliques utiles comme agents anti-diabétiques |
CA2741672A1 (fr) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Nouveaux agents antidiabetiques utiles avec des derives de benzimidazole cycliques |
US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
MX348131B (es) | 2011-02-25 | 2017-05-26 | Merck Sharp & Dohme | Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos. |
US9035059B2 (en) | 2011-03-14 | 2015-05-19 | Taisho Pharmaceutical Co., Ltd. | Nitrogen-containing condensed heterocyclic compound |
US20140045746A1 (en) | 2012-08-02 | 2014-02-13 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
ES2394349B1 (es) | 2012-08-29 | 2013-11-04 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii | Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar |
US9840512B2 (en) | 2013-02-22 | 2017-12-12 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2014139388A1 (fr) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques |
EP2970384A1 (fr) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonistes de la guanylate cyclase et leurs utilisations |
CA2905435A1 (fr) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions utiles pour le traitement de troubles gastro-intestinaux |
BR112015030326A2 (pt) | 2013-06-05 | 2017-08-29 | Synergy Pharmaceuticals Inc | Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos |
WO2015051496A1 (fr) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Composés tricycliques antidiabétiques |
WO2018106518A1 (fr) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Composés hétérocycliques antidiabétiques |
WO2018118670A1 (fr) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Composés de spirochromane antidiabétiques |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0091749A3 (fr) * | 1982-04-08 | 1984-12-05 | Beecham Group Plc | Dérivés de l'éthanolamine, procédé pour leur préparation et compositions pharmaceutiques les contenant |
US5451677A (en) * | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
-
1995
- 1995-04-18 IL IL11341095A patent/IL113410A/xx not_active IP Right Cessation
- 1995-04-21 NZ NZ284718A patent/NZ284718A/en unknown
- 1995-04-21 EP EP95917116A patent/EP0757674A1/fr not_active Ceased
- 1995-04-21 AU AU23937/95A patent/AU687558B2/en not_active Ceased
- 1995-04-21 SK SK1361-96A patent/SK136196A3/sk unknown
- 1995-04-21 HU HU9602951A patent/HUT76442A/hu unknown
- 1995-04-21 WO PCT/US1995/004956 patent/WO1995029159A1/fr not_active Application Discontinuation
- 1995-04-21 CZ CZ963151A patent/CZ315196A3/cs unknown
- 1995-04-21 CA CA002187932A patent/CA2187932A1/fr not_active Abandoned
- 1995-04-21 PL PL95316969A patent/PL316969A1/xx unknown
- 1995-04-21 JP JP52779795A patent/JP3149186B2/ja not_active Expired - Fee Related
- 1995-04-21 CN CN95192821A patent/CN1149869A/zh active Pending
-
1996
- 1996-10-25 NO NO964548A patent/NO964548L/no not_active Application Discontinuation
- 1996-10-25 FI FI964314A patent/FI964314A/fi unknown
Also Published As
Publication number | Publication date |
---|---|
IL113410A0 (en) | 1995-07-31 |
NO964548L (no) | 1996-12-23 |
HUT76442A (en) | 1997-09-29 |
JPH09512275A (ja) | 1997-12-09 |
PL316969A1 (en) | 1997-03-03 |
AU687558B2 (en) | 1998-02-26 |
WO1995029159A1 (fr) | 1995-11-02 |
AU2393795A (en) | 1995-11-16 |
SK136196A3 (en) | 1997-05-07 |
HU9602951D0 (en) | 1996-12-30 |
IL113410A (en) | 1999-11-30 |
MX9605192A (es) | 1997-09-30 |
CN1149869A (zh) | 1997-05-14 |
JP3149186B2 (ja) | 2001-03-26 |
CZ315196A3 (en) | 1997-08-13 |
EP0757674A1 (fr) | 1997-02-12 |
FI964314A0 (fi) | 1996-10-25 |
FI964314A (fi) | 1996-10-25 |
NO964548D0 (no) | 1996-10-25 |
NZ284718A (en) | 1998-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2187932A1 (fr) | Sulfamides substitues utilises comme agonistes selectifs vis-a-vis des recepteurs .beta.3-adrenergiques, pour le traitement du diabete et de l'obesite | |
US5561142A (en) | Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity | |
US5705515A (en) | Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity | |
US5541197A (en) | Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity | |
JP6861858B2 (ja) | Ssao阻害剤 | |
AU712057B2 (en) | Oxadiazole benzenesulfonamides as selective beta3 agonists for the treatment of diabetes and obesity | |
EP0611003B1 (fr) | Phénylsulfonamides substitués comme B3-agonistes selectives pour le traitement du diabète et de l'obésité | |
CA2305802C (fr) | Derives amides ou sels desdits derives | |
AU699138B2 (en) | Substituted biphenyl isoxazole sulfonamides | |
US8633175B2 (en) | Compounds as antagonists or inverse agonists at opioid receptors | |
EP1194144B1 (fr) | Composes antibacteriens | |
US20120053165A1 (en) | Novel Phenyl Imidazoles and Phenyl Triazoles As Gamma-Secretase Modulators | |
CN103772239B (zh) | 酰胺和脒衍生物和其用途 | |
EP0636130A1 (fr) | Composes azacycliques | |
JP2013534229A (ja) | バニロイド受容体リガンドとしての置換された環状カルボキサミド誘導体および尿素誘導体 | |
AU714701B2 (en) | Novel thiophene derivative and pharmaceutical composition thereof | |
AU751015B2 (en) | Novel sulfonamide substituted chroman derivatives useful as beta-3 adrenoreceptor agonists | |
US6034106A (en) | Oxadiazole benzenesulfonamides as selective β3 Agonist for the treatment of Diabetes and Obesity | |
US6903218B2 (en) | Sulfonamide substituted chroman derivatives | |
JPH08508031A (ja) | 5‐ht1aリガンドとしてのアミド誘導体 | |
US6232337B1 (en) | Selective β3 adrenergic agonists | |
JP2010138072A (ja) | 新規な縮合ピロール誘導体 | |
Fisher et al. | Substituted Sulfonamides as Selective β3 Agonists for the Treatment of Diabetes and Obesity | |
JP2566843B2 (ja) | ベンゾチアジン誘導体、その製法、及び医薬品として又は医薬品の合成中間体としてのその適用 | |
MXPA96005192A (en) | Sulfonamides substituted as agonistasó3selectivas for the treatment of diabetes yobesi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |